The global generic drugs market is anticipated to grow at a CAGR of around 11.1% during the forecast period 2020 to 2027 and to reach around US$ 627.6 Bn by 2027.
Market Dynamics
Increase government focus on encouraging manufacturers to produce generic drugs with the focus to deliver cost-effective medication to consumers, coupled with an approach towards lowering healthcare spending are major factors expected to drive the growth of the global market. There is a substantial increase in the number of patients suffering from chronic diseases. Also, the percentage of patients not receiving care due to the high cost of services is also increasing. The regulatory bodies are focused on encouraging generic drug development so that patients can access affordable medications. According to the Generic Pharmaceutical Association, generic drugs accounted for 88% of all dispensed retail prescriptions in the U.S in 2014, while consuming only 28 % of total drug spending. The use of generics, where available, is estimated to have saved the U.S. healthcare system US$ 1.68 trillion between 2005 and 2014, with US$ 254 billion saved in 2014 alone. Generic medicines generated US$ 253 billion in savings for patients and taxpayers in 2016. In the last decade, the U.S. healthcare system has saved US$ 1.67 trillion due to the availability of low-cost generics. Savings for the two largest government healthcare programs, Medicare and Medicaid, totaled US$ 77 billion and US$ 37.9 billion, respectively in 2016. That means every Medicare enrollee saved an average US$ 1,883, while every Medicaid enrollee saved an average US$ 512. Introduction of innovative drugs from players is expected to support the growth of generic drugs regional market.
In 2021, Ajanta Pharma Limited, a drug manufacturing company received approval for “Northera (Droxidopa) Capsules” a generic medicine. The medicine is focused on the treatment of orthostatic dizziness or lightheadedness in adult patients with symptomatic neurogenic orthostatic hypotension.
In 2021, Unichem Laboratories Limited, a generic drug manufacturing company received approval for “Otezla (Apremilast) Tablets” a generic drug. The drug is for the treatment of adult patients with moderate to severe plaque psoriasis.
Factors such as stringent government regulations related to product approval and adverse effect of drugs are expected to hamper the growth of global generic drugs market. In addition, lack of awareness among consumers related to generic drugs is expected to challenge the growth of target market. However, high investment by major players, increasing clinical trial activities and rising demand for new generic drugs are factors expected to create new opportunities for players operating in the generic drugs market over the forecast period. In addition, increase in the number of licensing & partnering strategies in order to launch new products is expected to support the revenue transaction of the target market.
Segment Analysis by Region
The market in North America is expected to account for major revenue share in the global market due to increasing awareness of generic medications among consumers. In addition, presence of large number of players operating in the country and introduction of innovative solutions are factors supporting the regional growth.
The market in Asia Pacific is expected to witness faster growth in the generic drugs market in the coming years due to high healthcare spending by the government. Major players approach towards enhancing the business in emerging economies and focus on shifting the manufacturing units to developing countries for the development of low cost products are factors expected to boost the growth of the generic drugs market. According to India Brand Equity Foundation, India is the largest provider of generic drugs globally. Indian pharmaceutical sector supplies over 50% of global demand for various vaccines, 40% of generic demand in the US, and 25% of all medicine in the UK.
Competitive Landscape
The global generic drugs market is high highly competitive due to presence of large number of players and innovative product offerings. In addition, business expansion activities through partnerships and agreements are factors expected to further increase the competition.
Report coverage
|
Market
|
Global Generic Drugs Market
|
|
Analysis Period
|
2016 – 2027
|
|
Base Year
|
2019
|
|
Forecast Data
|
2020 – 2027
|
|
Market Stratification
|
Product Type, Application, Route Of Administration, Distribution Channel and
Geography
|
|
Regional Scope
|
North America, Europe, Asia Pacific, Latin America, and Middle East & Africa
|
|
Report Coverage
|
Market Trends, Drivers, Restraints, Competitive Analysis, Player Profiling,
Regulation Analysis
|
Generic Drugs Market Segment Analysis, 2019
The global generic drugs market is segmented into product type, application, route of administration, and distribution channel. The application segment is bifurcated into cardiovascular products, anti-infective drugs, anti-arthritis drugs, central nervous system drugs, anti-cancer drugs, respiratory products, and others. Among applications, the anti-cancer drug is expected to witness faster growth in the generic drugs market. The distribution channel segment is divided into hospitals, pharmacies, and others. Among distribution channel the hospital segment is expected to account for major revenue share in the global market. Players operating in the global generic drugs market are Abbott Laboratories, Teva Pharmaceutical Industries Ltd., ALLERGAN, Sandoz International GmbH, Mylan N.V., STADA Arzneimittel AG, Baxter International Inc., Eli Lilly and Company, GlaxoSmithKline Plc., and Pfizer Inc.
Market Segmentation
Market By Product Type
Simple Generics
Super Generics
Biosimilars
Market By Route of Administration
Oral
Topical
Injectable
Intra-Venous
Others
Market By Application
Cardiovascular Products
Anti-Infective Drugs
Anti-Arthritis Drugs
Central Nervous System Drugs
Anti-Cancer Drug
Respiratory Products
Others
Market By Distribution Channel
Hospitals
Pharmacies
Others
Market By Geography
North America
• U.S.
• Canada
Europe
• U.K.
• Germany
• France
• Spain
• Rest of Europe
Asia-Pacific
• China
• Japan
• India
• Australia
• South Korea
• Rest of Asia-Pacific
Latin America
• Brazil
• Mexico
• Rest of Latin America
Middle East & Africa
• GCC
• South Africa
• Rest of Middle East & Africa
CHAPTER 1. Industry Overview of Generic Drugs
1.1. Definition and Scope
1.1.1. Definition of Generic Drugs
1.1.2. Market Segmentation
1.1.3. Years Considered for the Study
1.1.4. Assumptions and Acronyms Used
1.1.4.1. Market Assumptions and Market Forecast
1.1.4.2. Acronyms Used in Global Generic Drugs Market
1.2. Summary
1.2.1. Executive Summary
1.2.2. Generic Drugs Market By Product Type
1.2.3. Generic Drugs Market By Route Of Administration
1.2.4. Generic Drugs Market By Application
1.2.5. Generic Drugs Market By Distribution Channel
1.2.6. Generic Drugs Market by Regions
CHAPTER 2. Research Approach
2.1. Methodology
2.1.1. Research Programs
2.1.2. Market Size Estimation
2.1.3. Market Breakdown and Data Triangulation
2.2. Data Source
2.2.1. Secondary Sources
2.2.2. Primary Sources
CHAPTER 3. Market Dynamics And Competition Analysis
3.1. Market Drivers
3.1.1. Driver 1
3.1.2. Driver 2
3.2. Restraints and Challenges
3.2.1. Restrain 1
3.2.2. Restrain 2
3.3. Growth Opportunities
3.3.1. Opportunity 1
3.3.2. Opportunity 2
3.4. Porter’s Five Forces Analysis
3.4.1. Bargaining Power of Suppliers
3.4.2. Bargaining Power of Buyers
3.4.3. Threat of Substitute
3.4.4. Threat of New Entrants
3.4.5. Degree of Competition
3.5. Market Concentration Ratio and Market Maturity Analysis of Generic Drugs Market
3.5.1. Go To Market Strategy
3.5.1.1. Introduction
3.5.1.2. Growth
3.5.1.3. Maturity
3.5.1.4. Saturation
3.5.1.5. Possible Development
3.6. Technological Roadmap for Generic Drugs Market
3.7. Value Chain Analysis
3.7.1. List of Key Manufacturers
3.7.2. List of Customers
3.7.3. Level of Integration
3.8. Cost Structure Analysis
3.8.1. Proportion of Manufacturing Cost Structure
3.8.1.1. Raw Material
3.8.1.2. Labor Cost
3.8.1.3. Manufacturing Expense
3.9. Regulatory Compliance
3.10. Competitive Landscape, 2019
3.10.1. Player Positioning Analysis
3.10.2. Key Strategies Adopted By Leading Players
CHAPTER 4. Manufacturing Plant Analysis
4.1. Manufacturing Plant Location and Establish Date of Major Manufacturers in 2019
4.2. R&D Status and Distribution Channel Source of Generic Drugs Major Manufacturers in 2019
CHAPTER 5. Generic Drugs Market By Product Type
5.1. Introduction
5.2. Generic Drugs Revenue By Product Type
5.2.1. Generic Drugs Revenue (US$ Mn) and Forecast, By Product Type, 2016-2027
5.2.2. Simple Generics
5.2.2.1. Simple Generics Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.3. Super Generics
5.2.3.1. Super Generics Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
5.2.4. Biosimilars
5.2.4.1. Biosimilars Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 6. Generic Drugs Market Revenue By Route Of Administration
6.1. Introduction
6.2. Generic Drugs Revenue (US$ Mn) By Route Of Administration
6.2.1. Generic Drugs Revenue (US$ Mn) and Forecast By Route Of Administration, 2016 - 2027
6.2.2. Oral
6.2.2.1. Oral Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.3. Topical
6.2.3.1. Topical Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.4. Injectable
6.2.4.1. Injectable Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.5. Intra-venous
6.2.5.1. Intra-venous Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
6.2.6. Others
6.2.6.1. Others Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 7. Generic Drugs Market By Application
7.1. Introduction
7.2. Generic Drugs Revenue (US$ Mn) By Application
7.2.1. Generic Drugs Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
7.2.2. Cardiovascular Products
7.2.2.1. Cardiovascular Products Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.3. Anti-Infective Drugs
7.2.3.1. Anti-Infective Drugs Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.4. Anti-Arthritis Drugs
7.2.4.1. Anti-Arthritis Drugs Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.5. Central Nervous System Drugs
7.2.5.1. Central Nervous System Drugs Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.6. Anti-Cancer Drug
7.2.6.1. Anti-Cancer Drug Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.7. Respiratory Products
7.2.7.1. Respiratory Products Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
7.2.8. Others
7.2.8.1. Others Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 8. Generic Drugs Market By Distribution Channel
8.1. Introduction
8.2. Generic Drugs Revenue (US$) By Distribution Channel
8.2.1. Generic Drugs Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
8.3. Hospitals
8.3.1. Hospitals Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
8.4. Pharmacies
8.4.1. Pharmacies Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
8.5. Others
8.5.1. Others Market Revenue (US$ Mn) and Growth Rate (%), 2016-2027
CHAPTER 9. North America Generic Drugs Market By Country
9.1. North America Generic Drugs Overview
9.2. U.S.
9.2.1. U.S. Generic Drugs Market Revenue (US$ Mn) and Forecast By Product Type, 2016-2027
9.2.2. U.S. Generic Drugs Market Revenue (US$ Mn) and Forecast By Route Of Administration, 2016-2027
9.2.3. U.S. Generic Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
9.2.4. U.S. Generic Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016-2027
9.3. Canada
9.3.1. Canada Generic Drugs Market Revenue (US$ Mn) and Forecast By Product Type, 2016-2027
9.3.2. Canada Generic Drugs Market Revenue (US$ Mn) and Forecast By Route Of Administration, 2016-2027
9.3.3. Canada Generic Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
9.3.4. Canada Generic Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016-2027
9.4. North America PEST Analysis
CHAPTER 10. Europe Generic Drugs Market By Country
10.1. Europe Generic Drugs Market Overview
10.2. U.K.
10.2.1. U.K. Generic Drugs Market Revenue (US$ Mn) and Forecast By Product Type, 2016-2027
10.2.2. U.K. Generic Drugs Market Revenue (US$ Mn) and Forecast By Route Of Administration, 2016-2027
10.2.3. U.K. Generic Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
10.2.4. U.K. Generic Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016-2027
10.3. Germany
10.3.1. Germany Generic Drugs Market Revenue (US$ Mn) and Forecast By Product Type, 2016-2027
10.3.2. Germany Generic Drugs Market Revenue (US$ Mn) and Forecast By Route Of Administration, 2016-2027
10.3.3. Germany Generic Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
10.3.4. Germany Generic Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016-2027
10.4. France
10.4.1. France Generic Drugs Market Revenue (US$ Mn) and Forecast By Product Type, 2016-2027
10.4.2. France Generic Drugs Market Revenue (US$ Mn) and Forecast By Route Of Administration, 2016-2027
10.4.3. France Generic Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
10.4.4. France Generic Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016-2027
10.5. Spain
10.5.1. Spain Generic Drugs Market Revenue (US$ Mn) and Forecast By Product Type, 2016-2027
10.5.2. Spain Generic Drugs Market Revenue (US$ Mn) and Forecast By Route Of Administration, 2016-2027
10.5.3. Spain Generic Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
10.5.4. Spain Generic Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016-2027
10.6. Rest of Europe
10.6.1. Rest of Europe Generic Drugs Market Revenue (US$ Mn) and Forecast By Product Type, 2016-2027
10.6.2. Rest of Europe Generic Drugs Market Revenue (US$ Mn) and Forecast By Route Of Administration, 2016-2027
10.6.3. Rest of Europe Generic Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016-2027
10.6.4. Rest of Europe Generic Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016-2027
10.7. Europe PEST Analysis
CHAPTER 11. Asia Pacific Generic Drugs Market By Country
11.1. Asia Pacific Generic Drugs Market Overview
11.2. China
11.2.1. China Generic Drugs Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
11.2.2. China Generic Drugs Market Revenue (US$ Mn) and Forecast By Route Of Administration, 2016 - 2027
11.2.3. China Generic Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
11.2.4. China Generic Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
11.3. Japan
11.3.1. Japan Generic Drugs Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
11.3.2. Japan Generic Drugs Market Revenue (US$ Mn) and Forecast By Route Of Administration, 2016 - 2027
11.3.3. Japan Generic Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
11.3.4. Japan Generic Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
11.4. India
11.4.1. India Generic Drugs Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
11.4.2. India Generic Drugs Market Revenue (US$ Mn) and Forecast By Route Of Administration, 2016 - 2027
11.4.3. India Generic Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
11.4.4. India Generic Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
11.5. Australia
11.5.1. Australia Generic Drugs Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
11.5.2. Australia Generic Drugs Market Revenue (US$ Mn) and Forecast By Route Of Administration, 2016 - 2027
11.5.3. Australia Generic Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
11.5.4. Australia Generic Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
11.6. South Korea
11.6.1. South Korea Generic Drugs Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
11.6.2. South Korea Generic Drugs Market Revenue (US$ Mn) and Forecast By Route Of Administration, 2016 - 2027
11.6.3. South Korea Generic Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
11.6.4. South Korea Generic Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
11.7. Rest of Asia-Pacific
11.7.1. Rest of Asia-Pacific Generic Drugs Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
11.7.2. Rest of Asia-Pacific Generic Drugs Market Revenue (US$ Mn) and Forecast By Route Of Administration, 2016 - 2027
11.7.3. Rest of Asia-Pacific Generic Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
11.7.4. Rest of Asia-Pacific Generic Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
11.8. Asia Pacific PEST Analysis
CHAPTER 12. Latin America Generic Drugs Market By Country
12.1. Latin America Generic Drugs Market Overview
12.2. Brazil
12.2.1. Brazil Generic Drugs Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
12.2.2. Brazil Generic Drugs Market Revenue (US$ Mn) and Forecast By Route Of Administration, 2016 - 2027
12.2.3. Brazil Generic Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
12.2.4. Brazil Generic Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
12.3. Mexico
12.3.1. Mexico Generic Drugs Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
12.3.2. Mexico Generic Drugs Market Revenue (US$ Mn) and Forecast By Route Of Administration, 2016 - 2027
12.3.3. Mexico Generic Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
12.3.4. Mexico Generic Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
12.4. Rest of Latin America
12.4.1. Rest of Latin America Generic Drugs Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
12.4.2. Rest of Latin America Generic Drugs Market Revenue (US$ Mn) and Forecast By Route Of Administration, 2016 - 2027
12.4.3. Rest of Latin America Generic Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
12.4.4. Rest of Latin America Generic Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 – 2027
12.5. Latin America PEST Analysis
CHAPTER 13. Middle East & Africa Generic Drugs Market By Country
13.1. Middle East & Africa Generic Drugs Market Overview
13.2. Saudi Arabia
13.2.1. Saudi Arabia Generic Drugs Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
13.2.2. Saudi Arabia Generic Drugs Market Revenue (US$ Mn) and Forecast By Route Of Administration, 2016 - 2027
13.2.3. Saudi Arabia Generic Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
13.2.4. Saudi Arabia Generic Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
13.3. UAE
13.3.1. UAE Generic Drugs Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
13.3.2. UAE Generic Drugs Market Revenue (US$ Mn) and Forecast By Route Of Administration, 2016 - 2027
13.3.3. UAE Generic Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
13.3.4. UAE Generic Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 - 2027
13.4. Rest of Middle East & Africa
13.4.1. Rest of Middle East & Africa Generic Drugs Market Revenue (US$ Mn) and Forecast By Product Type, 2016 - 2027
13.4.2. Rest of Middle East & Africa Generic Drugs Market Revenue (US$ Mn) and Forecast By Route Of Administration, 2016 - 2027
13.4.3. Rest of Middle East & Africa Generic Drugs Market Revenue (US$ Mn) and Forecast By Application, 2016 - 2027
13.4.4. Rest of Middle East & Africa Generic Drugs Market Revenue (US$ Mn) and Forecast By Distribution Channel, 2016 – 2027
13.5. Middle East & Africa PEST Analysis
CHAPTER 14. PLAYER ANALYSIS OF GENERIC DRUGS
14.1. Generic Drugs Market Company Share Analysis
14.2. Competition Matrix
14.2.1. Competitive Benchmarking of key players by price, presence, market share, and R&D investment
14.2.2. New Product Launches and Product Enhancements
14.2.3. Mergers And Acquisition In Global Generic Drugs Market
CHAPTER 15. COMPANY PROFILE
15.1. Abbott Laboratories
15.1.1. Company Snapshot
15.1.2. Business Overview
15.1.3. Financial Overview
15.1.3.1. Revenue (US$ Mn), 2019
15.1.3.2. Abbott Laboratories 2019 Generic Drugs Business Regional Distribution
15.1.4. Product/ Service and Specification
15.1.5. Manufacturing Plant Footprint Analysis
15.2. Teva Pharmaceutical Industries Ltd.
15.3. ALLERGAN
15.4. Sandoz International GmbH
15.5. Mylan N.V.
15.6. STADA Arzneimittel AG
15.7. Baxter International Inc.
15.8. Eli Lilly and Company
15.9. GlaxoSmithKline Plc.
15.10. Pfizer Inc
15.11. Others
